CAD 0.35
(6.15%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2022 | -5.49 Million CAD | -36.51% |
2021 | -4.02 Million CAD | -2771.62% |
2020 | -140.05 Thousand CAD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 Q3 | 165.98 Thousand CAD | 94.05% |
2023 Q2 | 85.53 Thousand CAD | 137.52% |
2023 Q1 | -227.96 Thousand CAD | 66.44% |
2022 Q4 | -679.29 Thousand CAD | 25.54% |
2022 Q3 | -912.24 Thousand CAD | 71.06% |
2022 Q2 | -3.15 Million CAD | -322.19% |
2022 Q1 | -746.64 Thousand CAD | -35.42% |
2022 FY | - CAD | -36.51% |
2021 Q1 | -38.21 Thousand CAD | -15.63% |
2021 FY | - CAD | -2771.62% |
2021 Q2 | 161.36 Thousand CAD | 522.29% |
2021 Q4 | -551.35 Thousand CAD | 83.27% |
2021 Q3 | -3.29 Million CAD | -2142.43% |
2020 FY | - CAD | 0.0% |
2020 Q4 | -33.04 Thousand CAD | 0.0% |
2020 Q2 | -33.06 Thousand CAD | 0.0% |
2019 Q4 | -33.24 Thousand CAD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Algernon Pharmaceuticals Inc. | -4.98 Million CAD | -10.217% |
Asep Medical Holdings Inc | -8.13 Million CAD | 32.517% |
BetterLife Pharma Inc. | -3.19 Million CAD | -72.035% |
BioVaxys Technology Corp. | -7.68 Million CAD | 28.578% |
ChitogenX Inc. | -2.69 Million CAD | -103.802% |
Rapid Dose Therapeutics Corp. | -3.02 Million CAD | -81.518% |
Defence Therapeutics Inc. | -12.67 Million CAD | 56.686% |
Entheon Biomedical Corp. | 13.99 Thousand CAD | 39336.997% |
Gemina Laboratories Ltd. | -5.17 Million CAD | -6.079% |
Glow Lifetech Corp. | -1.26 Million CAD | -334.7% |
Lexston Life Sciences Corp. | -648.32 Thousand CAD | -746.866% |
Pharmala Biotech Holdings Inc. | -710.18 Thousand CAD | -673.099% |
Doseology Sciences Inc. | -319.47 Thousand CAD | -1618.564% |
MYND Life Sciences Inc. | -1.82 Million CAD | -200.813% |
Nova Mentis Life Science Corp. | -1.2 Million CAD | -356.661% |
PharmaTher Holdings Ltd. | -3.04 Million CAD | -80.406% |
PreveCeutical Medical Inc. | -955.08 Thousand CAD | -474.861% |